Pace of new drug approvals rise—and so do their price tags

February 3, 2016

Last year, more new drugs reached the market than in any year since 1996. But many have six-figure price tags for a year's worth of treatment and deliver only incremental health benefits. What does this mean for patients and the pharmaceutical industry? The cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, parses the 2015 crop of therapies and who might benefit.

Lisa Jarvis, a senior correspondent at C&EN, reports that the Food and Drug Administration (FDA) approved 45 new drug products last year. Of those, one third fell into a class of compounds called biologics, which include antibodies, peptides and enzymes. Nearly half are designed to treat "orphan" diseases, conditions that affect fewer than 200,000 people each. Different types of cancer are also targeted by several of the new treatments.

Various changes at the FDA appear to be helping to speed up the drug pipeline, which serves pharmaceutical companies well. Industry watchers expect more than a dozen of the new therapies will be blockbusters and top $1 billion in annual sales. But the impact on patients will be less cut-and-dried. Although one cancer drug could potentially prolong patients' lives by years, others might add only months at great cost. A dozen approved therapies for cancer and other conditions are expected to come with price tags between $100,000 and $310,000 per year.

Explore further: What 2015 reveals about trends in the pharmaceutical industry

More information: The Year in New Drugs - cen.acs.org/articles/94/i5/Year-New-Drugs.html

Related Stories

What 2015 reveals about trends in the pharmaceutical industry

December 9, 2015

As the year comes to an end, a survey of the hottest pharma news stories from the past year illustrates industry trends from megadeals to drug approvals. A suite of stories in Chemical & Engineering News (C&EN), the weekly ...

A strong, year-end finish for the pharmaceutical industry

December 10, 2014

As 2014 comes to a close, pharmaceutical companies have much to celebrate. An article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, takes a look back at the milestones the ...

FDA drug approvals reached 18-year high in 2014

January 2, 2015

The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.

Recommended for you

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

greenonions
not rated yet Feb 03, 2016
A dozen approved therapies for cancer and other conditions are expected to come with price tags between $100,000 and $310,000 per year.
We cannot afford our health care system. It has become totally insane. Dialysis costs $3,000 per treatment 3X a week. The kidney transplant is around $50,000 - and the anti rejection drugs are similar cost to the dialysis - for the rest of your life. We have gone into a bizarre world - of crazy prices - but you die if you don't get the treatment. Future generations will look upon us as pathologically insane (the last statement is an opinion).

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.